Giełdanowski J
Arch Immunol Ther Exp (Warsz). 1983;31(5):621-9.
The investigations have been carried out concerning the effectiveness of compound ITCl p-chlorophenylamide of 3-methyl-5-benzoylaminoizothiazole-4-carboxylic acid in the therapy of experimental, virus keratitis. Changes occurring on the cornea were morphologically determined and the intensity of the reaction, which per continuitatem penetrates deeper parts of the anterior eye chamber was estimated in the aqueous humor, applying biochemical factors. It has been stated that the drug in question, when applied locally, significantly weakens keratitis caused by herpes virus or by vesicular stomatitis virus. It limits the expansion of the inflammatory reaction, accelerates the reparation processes of the cornea, and causes the reparation changes not to damage the cornea optical transparence or renders the damage weaker. The conclusion has been drawn that the therapeutic effect of the drug is due to its antiviral and anti-inflammatory effect which has been revealed before.
已经对3-甲基-5-苯甲酰氨基异噻唑-4-羧酸的化合物ITCl对氯苯酰胺治疗实验性病毒性角膜炎的有效性进行了研究。通过形态学确定角膜上发生的变化，并应用生化因素在房水中评估反应强度，该反应持续不断地穿透眼前房的深部。已经表明，所讨论的药物局部应用时，可显著减轻由疱疹病毒或水疱性口炎病毒引起的角膜炎。它限制炎症反应的扩展，加速角膜的修复过程，并使修复变化不会损害角膜的光学透明度或使损害减轻。得出的结论是，该药物的治疗效果归因于其先前已显示的抗病毒和抗炎作用。
